Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants

NCT ID: NCT01446926

Last Updated: 2018-01-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 280 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-09-30
• Study Completion Date: 2013-06-30

Brief Summary

This study is designed to explore the safety and tolerability of an investigational pneumococcal vaccine through a step-down enrollment.

Primary Objective:

• To evaluate the safety and tolerability of an investigational pneumococcal vaccine.

Secondary Objective:

• To evaluate the immunogenicity of an investigational pneumococcal vaccine.

Detailed Description

All adult participants will receive a single injection of study vaccine or placebo. After satisfactory safety evaluation, toddler participants will receive a single injection of study vaccine or placebo. After satisfactory safety evaluation, infant participants will receive 3 injections of study vaccine or placebo in dose-ascending order (low, medium, and high dose), with a safety evaluation after each dose level before the study proceeds to the next higher dose. All participants will undergo immunogenicity testing and monitoring for safety.

Conditions

Pneumonia; Pneumococcal Infections; Streptococcus Pneumoniae Infections

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Group 1: Adults High Dose (Formulation 1)

Adults who will receive a single injection of high dose investigational Pneumococcal vaccine

Group Type: EXPERIMENTAL

Pneumococcal Vaccine High Dose (Formulation 1)

Intervention Type: BIOLOGICAL

0.5 mL, Intramuscular

Group 2: Adults Placebo

Adult participants who will receive an injection of placebo

Group Type: PLACEBO_COMPARATOR

Tris buffered saline (Placebo)

Intervention Type: BIOLOGICAL

0.5 mL, Intramuscular

Group 3: Toddlers High Dose (Formulation 1)

Toddlers who will receive a single injection of high dose Pneumococcal vaccine

Group Type: EXPERIMENTAL

Pneumococcal Vaccine High Dose (Formulation 1)

Intervention Type: BIOLOGICAL

0.5 mL, Intramuscular

Group 4: Toddlers Placebo

Toddlers who will receive a single injection of placebo

Group Type: PLACEBO_COMPARATOR

Tris buffered saline (Placebo)

Intervention Type: BIOLOGICAL

0.5 mL, Intramuscular

Group 5: Infants Low Dose (Formulation 2)

Infants who will receive 3 injections of low dose low dose Pneumococcal vaccine

Group Type: EXPERIMENTAL

Pneumococcal Vaccine Low Dose (Formulation 2)

Intervention Type: BIOLOGICAL

0.5 mL, Intramuscular

Group 6: Infants Placebo

Infants who will receive 3 injections of placebo

Group Type: PLACEBO_COMPARATOR

Tris buffered saline (Placebo)

Intervention Type: BIOLOGICAL

0.5 mL, Intramuscular

Group 7: Infants Middle Dose (Formulation 3)

Infants who will receive 3 injections of middle dose Pneumococcal vaccine

Group Type: EXPERIMENTAL

Pneumococcal Vaccine Middle Dose (Formulation 3)

Intervention Type: BIOLOGICAL

0.5 mL, Intramuscular

Group 8: Infants Middle Dose (Formulation 4)

Infants who will receive 3 injections of middle dose Pneumococcal vaccine

Group Type: EXPERIMENTAL

Pneumococcal Vaccine Middle Dose (Formulation 4)

Intervention Type: BIOLOGICAL

0.5 mL, Intramuscular

Group 9: Infants Placebo

Infants who will receive 3 injections of placebo

Group Type: PLACEBO_COMPARATOR

Tris buffered saline (Placebo)

Intervention Type: BIOLOGICAL

0.5 mL, Intramuscular

Group 10: Infants High Dose (Formulation 1)

Infants who will receive 3 injections of high dose Pneumococcal vaccine

Group Type: EXPERIMENTAL

Pneumococcal Vaccine High Dose (Formulation 1)

Intervention Type: BIOLOGICAL

0.5 mL, Intramuscular

Group 11: Infants Placebo

Infants who will receive 3 injections of placebo

Group Type: PLACEBO_COMPARATOR

Tris buffered saline (Placebo)

Intervention Type: BIOLOGICAL

0.5 mL, Intramuscular

Interventions

Pneumococcal Vaccine High Dose (Formulation 1)

0.5 mL, Intramuscular

Intervention Type: BIOLOGICAL

Tris buffered saline (Placebo)

0.5 mL, Intramuscular

Intervention Type: BIOLOGICAL

Pneumococcal Vaccine High Dose (Formulation 1)

0.5 mL, Intramuscular

Intervention Type: BIOLOGICAL

Tris buffered saline (Placebo)

0.5 mL, Intramuscular

Intervention Type: BIOLOGICAL

Pneumococcal Vaccine Low Dose (Formulation 2)

0.5 mL, Intramuscular

Intervention Type: BIOLOGICAL

Tris buffered saline (Placebo)

0.5 mL, Intramuscular

Intervention Type: BIOLOGICAL

Pneumococcal Vaccine Middle Dose (Formulation 3)

0.5 mL, Intramuscular

Intervention Type: BIOLOGICAL

Pneumococcal Vaccine Middle Dose (Formulation 4)

0.5 mL, Intramuscular

Intervention Type: BIOLOGICAL

Tris buffered saline (Placebo)

0.5 mL, Intramuscular

Intervention Type: BIOLOGICAL

Pneumococcal Vaccine High Dose (Formulation 1)

0.5 mL, Intramuscular

Intervention Type: BIOLOGICAL

Tris buffered saline (Placebo)

0.5 mL, Intramuscular

Intervention Type: BIOLOGICAL

Other Intervention Names

Tris buffered saline; Tris buffered saline; Tris buffered saline; Tris buffered saline; Tris buffered saline

Eligibility Criteria

Inclusion Criteria

Adults:

• Aged 18 to 50 years on the day of inclusion.
• Informed consent form has been signed and dated. If the subject is unable to read the informed consent form, a site-defined standard procedure will be followed to ensure subject understanding of the process and will be marked by the subject and signed by a witness.
• Able to attend all scheduled visits and to comply with all trial procedures.

Infants and Toddlers:

• Aged 6 to 7 weeks (42 to 49 days) for infants and 12 to 13 months for toddlers on the day of inclusion
• Born at full term of pregnancy (≥37 weeks) and having a weight ≥ 60% of the median weight for Bangladesh as measured by the "weight-to-length" index.
• Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative (and by an independent witness if required by local regulations). If the subject's parent(s) or other legally acceptable representative is unable to read the informed consent form, a procedure will be followed to ensure his/her understanding of the process and will be marked by the subject's parent(s) or other legally acceptable representative and signed by a witness.
• Subject and parent/guardian are able to attend all scheduled visits and to comply with all trial procedures.

Exclusion Criteria

• (Adults only): Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination and until at least 4 weeks after vaccination).
• Participation or planned participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination except if non-interventional follow-up for an earlier study (e.g., long-term surveillance).
• Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, or planned receipt of any vaccine in the 4 weeks following the trial vaccination.
• Previous vaccination against S. pneumoniae (in the previous 5 years).
• History of pneumococcal infection (confirmed microbiologically) within 5 years.
• Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response.
• Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
• Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances.
• Bleeding disorder, including thrombocytopenia contraindicating intramuscular (IM) vaccination, or receipt of anticoagulants in the 3 weeks preceding inclusion.
• Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
• Current alcohol abuse or drug addiction.
• Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.
• (Adults only): Identified as employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator.
• (Infants and Toddlers only): Parents or guardians identified as employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator.
• Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination.
• Receipt of oral or injected antibiotic therapy within 72 hours prior to any blood draw (for immunogenicity assessment).

• Minimum Eligible Age: 6 Weeks
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Sanofi Pasteur, a Sanofi Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Sanofi Pasteur Inc.

Locations

Dhaka, , Bangladesh

Countries

Bangladesh

References

Brooks WA, Chang LJ, Sheng X, Hopfer R; PPR02 Study Team. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study. Vaccine. 2015 Aug 26;33(36):4610-7. doi: 10.1016/j.vaccine.2015.06.078. Epub 2015 Jul 2.

Reference Type: RESULT

PMID: 26143615 (View on PubMed)

Other Identifiers

U1111-1117-7316

Identifier Type: OTHER

Identifier Source: secondary_id

PPR02

Identifier Type: -

Identifier Source: org_study_id